Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

Neuronetics (NASDAQ: STIM) will release first quarter 2026 financial and operating results before market open on Tuesday, May 5, 2026.

Rhea-AI Summary

Neuronetics (NASDAQ: STIM) will release first quarter 2026 financial and operating results before market open on Tuesday, May 5, 2026.

The company will host a conference call at 8:30 a.m. Eastern Time the same day, with a live listen-only webcast and telephone registration available for participants.

Argus Apr 21 session

-5.06% close to close Open Argus

Details

News Market Reaction – STIM

On Apr 21, the day this news came out, STIM closed 5.06% below the previous close.

Data tracked by StockTitan Argus for the Apr 21 session.

Key Figures

Q1 2026 results date: May 5, 2026 Conference call time: 8:30 a.m. Eastern Time

Q1 2026 results date

May 5, 2026

Planned release before market open

Conference call time

8:30 a.m. Eastern Time

Q1 2026 earnings call start time

Previous Conferences,earnings date Reports

1 past event · Latest: Mar 03

Same Type 1 event

1. Mar 03

   Earnings call date

   24h Move

   -1.6%

   Set date and time for Q4 2025 results and conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/3pztkve5. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com

Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com

References

¹ The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Neuronetics (STIM) report first quarter 2026 results?

Neuronetics will release first quarter 2026 financial and operating results prior to market open on May 5, 2026. According to the company, the release timing is set for before market open to allow the market to digest results ahead of trading, followed by a same-day conference call.

What time is the Neuronetics (STIM) Q1 2026 conference call on May 5, 2026?

The Neuronetics conference call is scheduled for 8:30 a.m. Eastern Time on May 5, 2026. According to the company, the call will review first quarter 2026 results and will be available via a live listen-only webcast and telephone registration.

How can investors listen to the Neuronetics (STIM) May 5, 2026 webcast?

Investors can listen via the live listen-only webcast available at the provided media-server link on May 5, 2026. According to the company, the webcast will broadcast the conference call and telephone participants may register in advance to join.

Is telephone participation available for Neuronetics (STIM) May 5, 2026 call?

Yes, telephone participation is available with prior registration for the May 5, 2026 call. According to the company, participants may register for telephone access and are recommended to join about 10 minutes before the 8:30 a.m. ET start.

Should attendees join the Neuronetics (STIM) conference call early?

It is recommended attendees join about 10 minutes prior to the 8:30 a.m. ET start on May 5, 2026. According to the company, early login ensures connection, proper audio setup, and timely participation in the live listen-only webcast or telephone bridge.

What will Neuronetics (STIM) cover on the May 5, 2026 conference call?

The company will review first quarter 2026 financial and operating results during the May 5, 2026 call at 8:30 a.m. ET. According to the company, the discussion will focus on reported results and related operational updates for investors and analysts.